 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| NUV-868 / Nuvation Bio
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1/2, N=657, Recruiting, Sponsor: Nuvation Bio Inc.
N=246 --> 657 | Trial completion date: Feb 2026 --> Nov 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
- ||| NUV-868 / Nuvation Bio, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Check out @NuvationB NUV-868 trial (BET inhibitor) + olaparib https://t.co/wMAjcAqPqB (Twitter) - Mar 29, 2023
- NUV-868 / Nuvation Bio, Lynparza (olaparib) / Merck (MSD), AstraZeneca
NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts (Section 20; Poster Board #2) - Mar 14, 2023 - Abstract #AACR2023AACR_8408;
P1/2
Our preclinical data demonstrate that NUV-868, a BD2-selective BET inhibitor, inhibits growth of tumor xenografts in combination with enzalutamide or olaparib and provides rationale for examination of these combinations in the clinic. An ongoing, phase 1 clinical study (NCT05252390) is evaluating NUV-868 as a monotherapy and in combination with olaparib or enzalutamide in patients with advanced solid tumors.
- |||| NUV-868 / Nuvation Bio
Enrollment open, Combination therapy, Monotherapy, Metastases: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 24, 2022
P1/2, N=246, Recruiting, Sponsor: Nuvation Bio Inc.
An ongoing, phase 1 clinical study (NCT05252390) is evaluating NUV-868 as a monotherapy and in combination with olaparib or enzalutamide in patients with advanced solid tumors. Not yet recruiting --> Recruiting
- ||||| NUV-868 / Nuvation Bio
New P1/2 trial, Combination therapy, Monotherapy, Metastases: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 23, 2022
P1/2, N=246, Not yet recruiting, Sponsor: Nuvation Bio Inc.